VAV3 and rectal cancer: We found that for both groups of colon and rectal cancer patients, patients with colon and rectal cancers concomitant VAV3 overexpression had a significantly lower 10-year overall survival rate than those with colon and rectal cancers without VAV3 overexpression (Supplementary Fig. S1a and S1b, P = 0.002 and 0.021, respectively).